195 related articles for article (PubMed ID: 38785726)
1. The Construction and Application of a New Screening Method for Phosphodiesterase Inhibitors.
Gao C; Wang Z; Liu X; Sun R; Ma S; Ma Z; Wang Q; Li G; Zhang HT
Biosensors (Basel); 2024 May; 14(5):. PubMed ID: 38785726
[TBL] [Abstract][Full Text] [Related]
2. Development of Phosphodiesterase-Protein-Kinase Complexes as Novel Targets for Discovery of Inhibitors with Enhanced Specificity.
Tulsian NK; Sin VJ; Koh HL; Anand GS
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34063491
[TBL] [Abstract][Full Text] [Related]
3. Evidence for the activity of five adenosine-3',5'-monophosphate-degrading phosphodiesterase isozymes in the adult rat neocortex.
Sutor B; Mantell K; Bacher B
Neurosci Lett; 1998 Aug; 252(1):57-60. PubMed ID: 9756358
[TBL] [Abstract][Full Text] [Related]
4. Cyclic nucleotide phosphodiesterase (PDE) inhibitors: novel therapeutic agents for progressive renal disease.
Cheng J; Grande JP
Exp Biol Med (Maywood); 2007 Jan; 232(1):38-51. PubMed ID: 17202584
[TBL] [Abstract][Full Text] [Related]
5. Role of phosphodiesterases III and IV in the modulation of vascular cyclic AMP content by the NO/cyclic GMP pathway.
Eckly AE; Lugnier C
Br J Pharmacol; 1994 Oct; 113(2):445-50. PubMed ID: 7834194
[TBL] [Abstract][Full Text] [Related]
6. Natural Molecules as Talented Inhibitors of Nucleotide Pyrophosphatases/ Phosphodiesterases (PDEs).
Orhan IE; Rauf A; Saleem M; Khalil AA
Curr Top Med Chem; 2022; 22(3):209-228. PubMed ID: 34503407
[TBL] [Abstract][Full Text] [Related]
7. Experimental and investigational phosphodiesterase inhibitors in development for asthma.
Ntontsi P; Detta A; Bakakos P; Loukides S; Hillas G
Expert Opin Investig Drugs; 2019 Mar; 28(3):261-266. PubMed ID: 30678501
[TBL] [Abstract][Full Text] [Related]
8. Effect of phosphodiesterase (1B, 2A, 9A and 10A) inhibitors on central nervous system cyclic nucleotide levels in rats and mice.
Chen J; Zook D; Crickard L; Tabatabaei A
Neurochem Int; 2019 Oct; 129():104471. PubMed ID: 31121256
[TBL] [Abstract][Full Text] [Related]
9. Phosphodiesterase Inhibitors as a Therapeutic Approach to Neuroprotection and Repair.
Knott EP; Assi M; Rao SN; Ghosh M; Pearse DD
Int J Mol Sci; 2017 Mar; 18(4):. PubMed ID: 28338622
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic potential of phosphodiesterase inhibitors for cognitive amelioration in Alzheimer's disease.
Xi M; Sun T; Chai S; Xie M; Chen S; Deng L; Du K; Shen R; Sun H
Eur J Med Chem; 2022 Mar; 232():114170. PubMed ID: 35144038
[TBL] [Abstract][Full Text] [Related]
11. "cAMP-specific" phosphodiesterase contributes to cGMP degradation in cerebellar cells exposed to nitric oxide.
Bellamy TC; Garthwaite J
Mol Pharmacol; 2001 Jan; 59(1):54-61. PubMed ID: 11125024
[TBL] [Abstract][Full Text] [Related]
12. High-throughput screening of phosphodiesterase activity in living cells.
Rich TC; Karpen JW
Methods Mol Biol; 2005; 307():45-61. PubMed ID: 15988054
[TBL] [Abstract][Full Text] [Related]
13. An update on cyclic nucleotide phosphodiesterase (PDE) inhibitors: phosphodiesterases and drug selectivity.
Gupta R; Kumar G; Kumar RS
Methods Find Exp Clin Pharmacol; 2005 Mar; 27(2):101-18. PubMed ID: 15834463
[TBL] [Abstract][Full Text] [Related]
14. A fission yeast-based platform for phosphodiesterase inhibitor HTSs and analyses of phosphodiesterase activity.
Demirbas D; Ceyhan O; Wyman AR; Hoffman CS
Handb Exp Pharmacol; 2011; (204):135-49. PubMed ID: 21695638
[TBL] [Abstract][Full Text] [Related]
15. Phosphodiesterase in heart and vessels: from physiology to diseases.
Fu Q; Wang Y; Yan C; Xiang YK
Physiol Rev; 2024 Apr; 104(2):765-834. PubMed ID: 37971403
[TBL] [Abstract][Full Text] [Related]
16. Cyclic nucleotide phosphodiesterases (PDEs) in human osteoblastic cells; the effect of PDE inhibition on cAMP accumulation.
Ahlström M; Pekkinen M; Huttunen M; Lamberg-Allardt C
Cell Mol Biol Lett; 2005; 10(2):305-19. PubMed ID: 16010295
[TBL] [Abstract][Full Text] [Related]
17. Clinical and molecular genetics of the phosphodiesterases (PDEs).
Azevedo MF; Faucz FR; Bimpaki E; Horvath A; Levy I; de Alexandre RB; Ahmad F; Manganiello V; Stratakis CA
Endocr Rev; 2014 Apr; 35(2):195-233. PubMed ID: 24311737
[TBL] [Abstract][Full Text] [Related]
18. Role of cyclic AMP- and cyclic GMP-phosphodiesterases in the control of cyclic nucleotide levels and smooth muscle tone in rat isolated aorta. A study with selective inhibitors.
Schoeffter P; Lugnier C; Demesy-Waeldele F; Stoclet JC
Biochem Pharmacol; 1987 Nov; 36(22):3965-72. PubMed ID: 2825708
[TBL] [Abstract][Full Text] [Related]
19. Carboxyamidotriazole: a novel inhibitor of both cAMP-phosphodiesterases and cGMP-phosphodiesterases.
Guo L; Luo L; Ju R; Chen C; Zhu L; Li J; Yu X; Ye C; Zhang D
Eur J Pharmacol; 2015 Jan; 746():14-21. PubMed ID: 25446933
[TBL] [Abstract][Full Text] [Related]
20. Nanodomain Regulation of Cardiac Cyclic Nucleotide Signaling by Phosphodiesterases.
Kokkonen K; Kass DA
Annu Rev Pharmacol Toxicol; 2017 Jan; 57():455-479. PubMed ID: 27732797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
